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Abstract
The scientific basis for antenatal corticosteroids (ACS) for
women at risk of preterm birth has rapidly changed in recent
years. Two landmark trials—the Antenatal Corticosteroid
Trial and the Antenatal Late Preterm Steroids Trial—have
challenged the long-held assumptions on the comparative
health benefits and harms regarding the use of ACS for
preterm birth across all levels of care and contexts, including
resource-limited settings. Researchers, clinicians, programme
managers, policymakers and donors working in low-income
and middle-income countries now face challenging questions
of whether, where and how ACS can be used to optimise
outcomes for both women and preterm newborns.
In this article, we briefly present an appraisal of the current
evidence around ACS, how these findings informed WHO’s
current recommendations on ACS use, and the knowledge
gaps that have emerged in the light of new trial evidence.
Critical considerations in the generalisability of the
available evidence demonstrate that a true state of clinical
equipoise exists for this treatment option in low-resource
settings. An expert group convened by WHO concluded that
there is a clear need for more efficacy trials of ACS in these
settings to inform clinical practice.

The global burden and risks of preterm
birth
Preterm birth is defined as live births occurring
before 37 completed weeks of gestation.1 An estimated 14.9 million neonates were born preterm
in 2010, accounting for 11.1% of live births worldwide.2 The majority of all preterm births occur in
the late preterm period (34 to <37 weeks)—for
example, in the USA more than 70% of preterm
births in 2014 were born in the late preterm
period.3 It is estimated that more than 60% of
the world’s preterm births occur in sub-Saharan
African and South Asian countries.2

Key messages
What is already known about this topic?

►► Antenatal corticosteroids (ACS) have been
considered the gold standard treatment for reducing
preterm-associated neonatal morbidity and mortality
for decades. However, the unexpected findings of the
recently published Antenatal Corticosteroids Trial in
low-income and middle-income countries (LMICs)
have challenged long-held assumptions on the
comparative health benefits and harms of ACS use
in LMICs across of all levels of care.
►► In 2015, WHO recommended ACS use up to 34
weeks’ gestation with strict treatment criteria to
guide its use, in acknowledgement of unanswered
questions about safety and efficacy in hospitals in
low-resource countries.

New information

►► A reappraisal of the hallmark Cochrane review
evidence identified several limitations that
undermine generalisability to lower-income
countries. Furthermore, the recent Antenatal Late
Preterm Steroids trial conducted in tertiary centres
in the USA reported some benefits for late preterm
newborns. Questions still remain regarding the
applicability of this new evidence to hospitals in lowresource countries.
►► WHO convened an expert group that reviewed the
available evidence—the group agreed that efficacy
trials on ACS use for preterm birth in hospitals in lowresource countries are justified, to guide clinicians
and policymakers on whether, how and where ACS
can be used safely and effectively in these settings.

Prematurity can be a lethal condition,
particularly for those newborns born at
earlier gestational ages. Complications of
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preterm birth are the leading cause of death in children
under 5 years of age globally, accounting for 1.06 million
deaths (uncertainty range 0.935 to 1.179 million) of the
5.9 million deaths estimated to have occurred in 2015.4
Those preterm neonates who survive are at increased
risk of a wide range of respiratory, infectious, metabolic
and neurological morbidities. Preterm infants experience higher rates of respiratory distress syndrome,
bronchopulmonary dysplasia, necrotising enterocolitis,
kernicterus, hypoglycaemia, periventricular leucomalacia, seizures, intraventricular haemorrhage, cerebral
palsy, infections, feeding difficulties, hypoxic ischaemic
encephalopathy, retinopathy of prematurity, as well as
visual and hearing loss.5–16 Preterm birth and its sequelae
can have significant negative psychosocial and financial
impacts on families of preterm newborns.17–20
While the risks of mortality and morbidity affecting
preterm newborns are considerably more frequent at
lower gestational ages,11 late preterm infants (sometimes called ‘near-term’) still experience significantly
higher risks compared with babies born at term.21
A systematic review of more than 29 million infants
(mostly in high-income countries) found that,
compared with term birth, late preterm birth was associated with increased 28-day mortality (Risk Ratio (RR)
5.9, 95% CI 5.0 to 6.9) and 1-year mortality (RR 3.7,
95% CI 2.9 to 4.6).21

Antenatal corticosteroids
Antenatal corticosteroids (ACS) have long been
regarded as a cornerstone intervention in mitigating
the adverse effects of preterm birth. The Cochrane
Collaboration logo is itself constructed from an early
ACS meta-analysis.22 The first randomised controlled
trial of ACS (betamethasone) in humans to prevent
respiratory distress syndrome was published in 1972.23
Since then, dozens more trials have been conducted,
exploring neonatal risks and benefits when given to
women at risk of preterm birth,24 the use of different
dosing regimens25 and the use of ACS for preventing
neonatal respiratory morbidity after elective caesarean
section at term.26
In March 2017, the updated Cochrane systematic review
on ACS for accelerating fetal lung maturation for women
at risk of preterm birth was published, including 30 trials
of 7774 women and 8158 infants.27 The findings are
similar to earlier iterations, showing striking reductions
in neonatal mortality and several morbidity outcomes
(box 1). This analysis has contributed to the widespread
(and often overly liberal) use of ACS for women at risk
of preterm birth, including in low-income and middle-income countries (LMICs).28
However, there are several critical limitations in the
Cochrane review evidence base that complicate their
application to many hospitals in LMICs, as discussed
below.
2

A reappraisal of the Cochrane review evidence
Trial settings
The 30 trials were conducted in higher-level hospital
settings, in high-income (20 trials) and upper middle-income (nine trials) countries, except one trial that was
conducted in Tunisia (a lower middle income country).29
It seems reasonable to assume that the level of maternal
and newborn care provided reflected the best available at
the time the studies were conducted, including the accuracy of gestational age estimation for recruited women.
Comparatively, no placebo-controlled efficacy trials of
ACS have been conducted in low-income countries,
where the rates of maternal and newborn mortality and
morbidity are higher, and the level of health and human
resources available to manage pregnant women and
preterm infants substantially lower. Despite this, ACS are
routinely used in facilities in many lower-income countries.30
Age of the trials and risk of bias
The Antenatal Late Preterm Steroid (ALPS) Trial
published in 201631 (discussed further below) is the
largest trial in this meta-analysis. Among the other 29
trials, three-quarters of participants were randomised
more than 20 years ago. While the age of a trial itself is
not necessarily an indication of poor quality, reports of
older trials often contain no or insufficient information
to fully assess their risk of bias. Importantly, the context
of maternal and newborn care has changed substantially
since those trials were conducted—interventions such
as oxygen therapy, continuous positive airway pressure
(CPAP), thermal care, nutritional support, mechanical
ventilation and surfactant are more widely used now than
in past decades. Given these improvements, the anticipated benefits of ACS may therefore not be as large as
expected. It is noteworthy that infant mortality due to
respiratory distress syndrome in the USA has decreased
significantly since the 1970s,32 with large reductions
achieved prior to the widespread use of ACS.33
Heterogeneity in participants between trials
There is considerable heterogeneity in the eligibility
criteria used in these trials; table 1 gives the different gestational age ranges used. Trials have included or excluded
women with certain obstetric characteristics—women in
spontaneous preterm labour, women with premature prelabour rupture of membranes, women with planned preterm
birth and women with high-risk obstetric conditions (such
as multiple pregnancies, diabetes, infection and hypertensive disorders). The pooling of data when trials are so
diverse may be inappropriate. Furthermore, the preterm
birth rate after randomisation among women recruited to
these trials was generally very high. At least 11 trials had
preterm birth rates at or near 100%, suggesting that these
trials recruited women who had a very high likelihood of
delivering preterm. It also raises the possibility that some
infants exposed to ACS were ultimately born at term, but
were not captured or included for analysis.
Vogel JP, et al. BMJ Glob Health 2017;2:e000398. doi:10.1136/bmjgh-2017-000398
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Table 1 Gestational age ranges used in eligibility criteria
for antenatal corticosteroids administration, reproduced
with permission from updated Cochrane review24
Study

Gestational age range

Amorim 1999
Attawattanakul
2015

28 weeks 0 days to 34 weeks 6 days
34 weeks 0 days to 36 weeks 6 days

Balci 2010

34 weeks 0 days to 36 weeks 6 days

Block 1977

Up to 36 weeks 6 days*

Cararach 1991

28 weeks 0 days to 30 weeks 6 days

Carlan 1991

28 weeks 0 days to 30 weeks 6 days

Collaborative
1981

26 weeks 0 days to 37 weeks 0 days

Dexiprom 1999

28 weeks 0 days to 34 weeks 6 days
(or estimated fetal weight 1000–2000 g)

Doran 1980

24 weeks 0 days to 34 weeks 6 days

Fekih 2002

26 weeks 0 days to 34 weeks 6 weeks

Gamsu 1989

Up to 34 weeks 6 days*

Garite 1992

24 weeks 0 days to 27 weeks 6 days

Goodner 1979

Up to 33 weeks 6 days*

Gyamfi34 weeks 0 days to 36 weeks 6 days
Bannerman 2016
Kari 1994

24 weeks 0 days to 31 weeks 6 days

Lewis 1996

24 weeks 0 days to 34 weeks 6 days

Liggins 1972

24 weeks 0 days to 36 weeks 6 days

Lopez 1989

27 weeks 0 days to 35 weeks 0 days

Mansouri 2010

25 weeks 0 days to 36 weeks 6 days

Morales 1989

26 weeks 0 days to 34 weeks 6 days

Nelson 1985

28 weeks 0 days to 34 weeks 6 days

Parsons 1988

25 weeks 0 days to 32 weeks 6 days

Porto 2011

34 weeks 0 days to 36 weeks 6 days

Qublan 2001

27 weeks 0 days to 34 weeks 6 days

Schutte 1980

26 weeks 0 days to 32 weeks 6 days

Shanks 2010

34 weeks 0 days to 36 weeks 6 days

Silver 1996

24 weeks 0 days to 29 weeks 6 days

Taeusch 1979
Teramo 1980

Up to 33 weeks 6 days*
28 weeks 0 days to 35 weeks 6 days

*Lower gestational age limit not specified.

Measurement of neonatal mortality
Twenty-two trials reported on neonatal death; however, none
were independently powered to detect a difference in this
outcome. All were facility based, and in general did not specify
what definition of neonatal death was used, nor how the
follow-up of newborns to ascertain vital status was conducted.
Importantly, several trials had excluded women postrandomisation, some of which may have directly impacted on
detection of neonatal mortality. In total, this meta-analysis
included 551 deaths in 6729 newborns (a mortality rate of
8.2% overall). In low-resource countries, newborn mortality
rates in preterm newborns can be two to three times higher.
Vogel JP, et al. BMJ Glob Health 2017;2:e000398. doi:10.1136/bmjgh-2017-000398

Only seven trials had ≥200 newborns each, accounting
for 78% of the total sample size for this outcome. The ALPS
Trial, by far the largest trial for this outcome, reported two
deaths in the intervention arm and zero in the control
arm (a non-significant difference). None of the six largest
trials independently reported a reduction in the risk of
neonatal death. The seventh (Amorim et al) randomised
218 pregnant women and reported a 50% risk reduction
in neonatal death (RR 0.50, 95% CI 0.28 to 0.89); however,
this trial included only women with severe pre-eclampsia.34
The remaining 15 trials were all small (<200 newborns
each); three trials had <100 newborns. Only four small trials
reported independent reductions in the risk of newborn
mortality, with effect sizes exceeding 50%.29 35–37 The
impact of a large number of small trials on the summary
estimate is of concern. The funnel plot for this outcome
does not indicate an obvious publication bias, but this does
not rule out the possibility.38

The Antenatal Corticosteroids Trial
In 2015, Althabe and colleagues published findings from
The Antenatal Corticosteroids Trial (ACT). ACT was a
community-based, cluster-randomised trial conducted in
six LMICs: Argentina, Guatemala, India, Kenya, Pakistan
and Zambia.39 The trial aimed to evaluate the feasibility,
effectiveness and safety of a multifaceted intervention designed to increase the use of ACS at all levels of
healthcare. The intervention included ACS commodity
procurement, as well as training and tools for health
providers to recognise at-risk women, estimate gestational age and administer dexamethasone. The primary
outcome was neonatal death at 28 completed days among
liveborn neonates at less than fifth percentile for birth
weight (as a proxy for preterm births, because of inadequate gestational age information).
ACT included 101 clusters in six countries, capturing
nearly 100 000 live births. The use of ACS increased in
the intervention arm for women with a less-than-fifthpercentile infant (45% vs 10%), but also for all women,
regardless of her baby’s birth weight (12% vs 2%). Only
16% of the women who were given ACS ultimately gave
birth to a less-than-fifth-percentile newborn, highlighting
substantial overdiagnosis of imminent preterm birth and
overtreatment with ACS. Among the less-than-fifth-percentile newborns, ACS use had no effect on neonatal
deaths (RR 0.96, 95% CI 0.87 to 1.06). However, among
all births, there were increased risks of neonatal mortality
(RR 1.12, 1.02–1.22) and stillbirth (RR 1.11, 1.02–
1.22)—a very unexpected and concerning finding. The
authors reported that the increased mortality was seemingly driven by increased mortality in infants above the
25th percentile for birth weight. Furthermore, the intervention was associated with an increased OR of suspected
maternal infection in women with less-than-fifth-percentile babies (OR 1.67, 95% CI 1.33 to 2.09), and all women
(OR 1.45, 95% CI 1.33 to 1.58).
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Box 1 Neonatal outcomes of antenatal corticosteroids for
accelerating fetal lung maturation from updated Cochrane
review27
►► 32% reduction in neonatal deaths (Risk Ratio (RR) 0.69, 95% CI
0.59 to 0.81; 22 studies of 7188 participants)
►► 35% reduction in respiratory distress syndrome (RDS) (average RR
0.66, 95% CI 0.56 to 0.77; 28 studies of 7764 participants)
►► 45% reduction in moderate and severe RDS (average RR 0.59,
95% CI 0.38 to 0.91; 6 studies of 1686 participants)
►► 46% reduction in intraventricular haemorrhage (average RR 0.55,
95% CI 0.40 to 0.76; 16 studies of 6093 participants)
►► 54% reduction in necrotising enterocolitis (RR 0.50, 95% CI 0.32 to
0.78; 10 studies of 4702 participants)
►► 43% reduction in infant systemic infection in the first 48 hours of
life (RR 0.60, 95% CI 0.41 to 0.88; 8 studies of 1753 participants)

While this complex intervention successfully increased
the use of ACS more than fourfold in low-resource
settings, the overall picture was alarming—lack of benefit
in the less-than-fifth-percentile newborns, evidence of
increased perinatal mortality in larger newborns and
the increase in suspected maternal infections. While the
exact causes are not known, the study group hypothesise
that maternal and newborn infections may play a role.40
WHO recommendations on use of ACS (2015)
How then should these two contrasting bodies of
evidence—30 randomized controlled trials largely from
high-resourced hospitals in higher-income countries,
and a large implementation trial in six LMICs—be
balanced? The WHO recommendations on interventions
to improve preterm birth outcomes were published in
2015, for which an updated search and meta-analysis was
conducted.41 WHO recommends ACS for women at risk
of preterm birth from 24 weeks to 34 weeks gestation in
settings where certain criteria are met (box 2).42 These
consensus-based treatment criteria were intended to
address the issues regarding safety of ACS in resource-limited settings. The recommendation remarks specify that
ACS should not be routinely administered in situations
where the gestational age cannot be confirmed (particularly when gestational age is suspected to be more than

Box 2 Antenatal corticosteroids treatment criteria in
the WHO recommendations to improve preterm birth
outcomes42
►► Gestational age assessment can be accurately undertaken
►► Preterm birth is considered imminent
►► There is no clinical evidence of maternal infection
►► Adequate childbirth care is available (including the capacity to
recognise and safely manage preterm labour and birth)
►► The preterm newborn can receive adequate care if needed
(including resuscitation, thermal care, feeding support, infection
treatment and safe oxygen use)

4

34 weeks), as the risk of neonatal harm may outweigh the
benefits.
The ACT Trial highlighted that scaling up ACS in
LMICs without more definitive evidence on benefits and
harms could prove detrimental to both mothers and
newborns. Given the uncertainties inherent in generalising the current evidence base to facilities in low-resource
settings, and the risk of harm at higher gestational
ages, the WHO guideline panel recommended further
research to inform ACS use and improve generalisability
to lower-resource settings.41
The Antenatal Late Preterm Steroids Trial
The findings of the Antenatal Late Preterm Steroids
(ALPS) Trial were published in early 2016 (after the
release of the WHO recommendations).31 This was a
multicentre, randomised trial in tertiary care centres in
the USA that recruited women with a singleton pregnancy, at high risk for preterm birth and at 34 weeks 0
days to 36 weeks 5 days of gestation. Participants were
randomised to receive up to two injections of betamethasone or matching placebo, 24 hours apart. The primary
outcome was a management-based, composite severe
adverse neonatal outcome relating to need for respiratory
support. It was defined as one or more of the use of CPAP
or high-flow nasal cannula for at least two consecutive
hours, supplemental oxygen with a fraction of inspired
oxygen of at least 0.30 for at least four continuous hours,
extracorporeal membrane oxygenation or mechanical
ventilation. Stillbirth and neonatal death within 72 hours
were included as competing events.
The authors reported that the primary outcome was
significantly reduced in the intervention arm, 11.6% vs
14.4% (RR 0.80; 95% CI 0.66 to 0.97). Other newborn
secondary outcomes (including severe respiratory
complications, transient tachypnoea of the newborn,
surfactant use and bronchopulmonary dysplasia) were
also significantly less frequent in the betamethasone
group, although neonatal hypoglycaemia was more
common in the betamethasone group (24.0% vs 15.0%;
RR 1.60; 95% CI 1.37 to 1.87). There were no apparent
differences in the incidence of chorioamnionitis, respiratory distress syndrome or neonatal sepsis.
The ALPS Trial findings were meta-analysed with
similar trials in a recent systematic review by Saccone
and Berghella, who explored the role of ACS in term
or near-term fetuses.26 The review included six trials,
comprising 5698 singleton pregnancies. The review
authors concluded that ACS at ≥34 weeks’ gestation
reduces neonatal respiratory morbidity, and that a single
course of corticosteroids can be considered for women at
risk of imminent late premature birth (34 weeks 0 days
to 36 weeks 6 days) gestation, as well as for the subgroup
of women undergoing planned caesarean delivery at ≥37
weeks’ gestation.
WHO does not currently recommend the use of ACS
in the late preterm period, given the lack of evidence
Vogel JP, et al. BMJ Glob Health 2017;2:e000398. doi:10.1136/bmjgh-2017-000398
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Table 2 Programmatic implications of conducting two concurrent trials of ACS, considering possible scenarios of effects on
newborn mortality outcome
Early preterm period (ACTION-I Trial)
Shows reduction in newborn
mortality
Late preterm period
(ACTION-II Trial)

Shows no
reduction in
Shows increase in
newborn mortality newborn mortality

Shows reduction in
Use ACS 26 to 36 weeks
Unlikely to occur
newborn mortality
Shows no reduction in Use ACS at 26 to <34 weeks
Do not use ACS
newborn mortality
Gestational age threshold not critical
for safety
Shows increase in
Use ACS at 26 to <34 weeks
Do not use ACS
newborn mortality
GA threshold is critical for safety

Unlikely to occur
Do not use ACS

Do not use ACS

ACS, antenatal corticosteroids; ACTION, Antenatal CorticosTeroids for Improving Outcomes in preterm Newborns.

of benefit at the time the WHO recommendations
were developed. While the findings of the ALPS Trial
suggest that ACS in the late preterm period could reduce
newborn respiratory morbidity (but not fetal or neonatal
mortality) in high-resource settings, it is not certain that
these findings—which relate largely to reducing the need
for newborn care interventions available in high-level
hospitals—can be replicated in hospitals in LMICs where
considerably fewer health and human resources are available. Late preterm ACS use might confer a mortality
benefit in low-resource settings, where rates of neonatal
mortality in late preterm newborns are unacceptably
high, but this is speculative.
The case for equipoise, and the need for efficacy
trials in low-resource settings
In November 2015, WHO convened a technical consultation of obstetricians, neonatologists and researchers
in preterm birth to review and discuss the knowledge
gaps around ACS use prior to 34 weeks. With the publication of the ALPS Trial in February 2016, an additional
meeting of researchers and technical advisors was held in
July 2016 to review the evidence around the late preterm
period.
Based on the evidence appraisal above, it was agreed
that there is a clear justification for further randomised
controlled trials to evaluate the efficacy of ACS in facility
settings in lower-income countries. While evidence
suggests that there may be a role for ACS in preterm
birth management in these settings, efficacy evidence
from hospitals in low-resource countries that balances
possible maternal, fetal and neonatal benefits and harms
is required to guide clinical practice.
The group noted that if the conduct of such an efficacy trial is limited to women at imminent risk of early
preterm birth (<34 weeks), future recommendations on
ACS use would continue to be restricted to this gestational age limit. This can complicate ACS scale-up in
most low-resource countries, where accurate gestational
age assessment is often not available. The outstanding
Vogel JP, et al. BMJ Glob Health 2017;2:e000398. doi:10.1136/bmjgh-2017-000398

question of possible benefits and harms for mothers and
late preterm babies will also remain unresolved.
If a separate, independently powered efficacy trial of
ACS in the late preterm period showed benefit, the public
health impact will be significant. Compared with early
preterm births, neonatal mortality rates are lower in late
preterm babies, but the prevalence is more than three
times larger. Even modest benefits (in the absence of
harms) would thus translate into substantive impacts on
preterm-associated morbidity, mortality and healthcare
utilisation. If neither benefits nor harms are demonstrated in the late preterm period, reliance on accurate
gestational age assessment around 34 weeks will be less
critical. The various scenarios are summarised in table 2.
This has led to the establishment of an international
research collaboration, called the WHO Antenatal
CorticosTeroids for Improving Outcomes in preterm
Newborns (WHO ACTION) Trials. With support from
the Bill and Melinda Gates Foundation, this collaboration will conduct two concurrent and independently
powered, hospital-based, placebo-controlled efficacy
trials of ACS (dexamethasone), which will recruit women
presenting to participating hospitals at imminent risk
of preterm birth. The ACTION-I trial will randomise
eligible women from 26 weeks 0 days to 33 weeks 6 days,
while the ACTION-II trial will randomise eligible women
from 34 weeks 0 days to 36 weeks 0 days. The trials will be
conducted in hospitals with a sufficient level of maternal
and newborn care in Bangladesh, India, Kenya, Nigeria
and Pakistan. These hospitals will be supported (where
necessary) with additional equipment and training, in
order to optimise gestational age dating, as well as care
of preterm newborns. When concluded, these two trials
will add more than 28 000 women to the Cochrane review
meta-analysis on this question, providing the needed trial
evidence on ACS use in low-resource countries.
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